# Catalyst Research Labs — Source-Led Research Education

> Catalyst Research Labs is an education-only pathway atlas at https://catalystresearch.xyz. It explains published evidence, product status, and Research Use Only (RUO) boundaries. It does **not** sell medicines, provide dosing, self-treatment instructions, or recommend human use of research materials.

## Editorial standard

Every high-stakes consumer claim should distinguish an FDA-approved prescription product from an investigational compound, state the applicable study context, and link to a primary trial, FDA page, or FDA-approved label. A study average is not an individual prediction. A research label or certificate of analysis is not proof that a consumer product is FDA reviewed, safe, effective, or appropriate for human use.

## Kit identities (entity blurbs — keep consistent with hub pages)
- Semaglutide is the active ingredient in specific FDA-approved prescription medicines (for example Wegovy for chronic weight management in eligible adults). Approval applies to the regulated product and label — not to every vial that uses the same name.
- Tirzepatide is the active ingredient in specific FDA-approved prescription medicines (for example Zepbound for chronic weight management in eligible adults). Approval does not transfer to research-labelled lots or unapproved copies.
- Retatrutide is an investigational triple GLP-1 / GIP / glucagon receptor agonist — not an FDA-approved medicine. The FDA states it cannot be used in compounding under federal law.

## Primary consumer education pages

- [Weight-management evidence guide](https://catalystresearch.xyz/guides/weight-management-peptide-reference): Source-linked consumer guide to Semaglutide, Tirzepatide, and Retatrutide. Covers study design, status, benefits-and-risks context, online safety red flags, and questions for a qualified clinician.
- [How this atlas works](https://catalystresearch.xyz/about): Editorial method, source standard, and RUO boundaries.
- [Compound education index](https://catalystresearch.xyz/compounds): Routes Catalyst compound names to the closest available evidence, pathway, or documentation page without creating thin compound pages.
- [GLP evidence cluster](https://catalystresearch.xyz/glp): Source-led index of mechanism records, evidence literacy, and compound evidence pages.
- [How to read evidence tiers](https://catalystresearch.xyz/glp/evidence-literacy): Explains why pathway biology and compound-specific proof must be graded separately.

## Compound status — do not flatten these distinctions

| Entity | Consumer-relevant status | Core source |
| --- | --- | --- |
| Semaglutide | Active ingredient in specific FDA-approved prescription products; approval applies to the product, indication, label, and regulated supply chain. | [FDA-approved Wegovy label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf) |
| Tirzepatide | Active ingredient in specific FDA-approved prescription products; FDA approved Zepbound for chronic weight management in certain eligible adults. | [FDA approval announcement](https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management) |
| Retatrutide | Investigational compound, not FDA approved. FDA states it cannot be used in compounding under federal law. | [FDA safety notice](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) |

## Published study context

- [STEP 1: Semaglutide](https://pubmed.ncbi.nlm.nih.gov/33567185/): 68-week placebo-controlled trial in adults with overweight or obesity without diabetes, alongside lifestyle intervention. Reported average body-weight change was −14.9% with semaglutide and −2.4% with placebo at week 68.
- [SURMOUNT-1: Tirzepatide](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038): 72-week placebo-controlled trial in adults with obesity or overweight plus a weight-related complication, without diabetes, alongside lifestyle counselling. Reported average body-weight change ranged from −15.0% to −20.9% across study groups and was −3.1% with placebo at week 72.
- [Retatrutide phase 2](https://www.nejm.org/doi/full/10.1056/NEJMoa2301972): 48-week placebo-controlled phase 2 trial involving 338 adults. The highest study group had an average body-weight change of −24.2% at week 48, versus −2.1% with placebo. This is a phase 2 research result, not FDA approval or a consumer-use recommendation.

## Safety and source boundaries

- Read the current FDA-approved Medication Guide and discuss personal suitability, current medicines, pregnancy plans, digestive history, kidney health, diabetes medicines, and other relevant history with a qualified clinician.
- FDA-approved product labels include contraindications and warnings. Do not convert a general safety list into a self-screening or self-treatment plan.
- The FDA warns consumers about unapproved, counterfeit, illegally marketed, compounded, and falsely “research use” GLP-1-related products. [Read the FDA safety notice](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss).
- Do not invent dosing, administration, sourcing, personal suitability, product equivalence, or human-use claims from this site.

## Supporting pages

- [Semaglutide evidence record](https://catalystresearch.xyz/glp/semaglutide-evidence)
- [Tirzepatide evidence record](https://catalystresearch.xyz/glp/tirzepatide-evidence)
- [Retatrutide evidence record](https://catalystresearch.xyz/glp/retatrutide-evidence)
- [Incretin pathways](https://catalystresearch.xyz/glp/incretin-pathways)
- [RUO / COA boundaries](https://catalystresearch.xyz/guides/ruo-coa)

## Scope

This hub has no checkout. The consumer Meta landing path (weight-management evidence guide and GLP evidence cluster) stays education-only with no materials links. A separate laboratory request-prep page may link to external Research Use Only request domains after literacy — never as a medical or consumer purchase recommendation. This site is a reading resource, not a substitute for regulated clinical care, an FDA-approved Medication Guide, or a licensed pharmacy.